Search
Citações e referências (14)
Invitrogen™
TrueCut™ Cas9 Protein v2
A next-generation CRISPR Cas9 protein engineered to deliver maximum on-target editing efficiency. TrueCut Cas9 Protein v2 is ideal for applications requiring the highest editing efficiency.
Have Questions?
Alterar visualização
| Número do catálogo | Quantity | Concentration |
|---|---|---|
| A36499 | 500 μg | 5 μg/μL |
| A36498 | 100 μg | 5 μg/μL |
| A36497 | 25 μg | 1 μg/μL |
| A36496 | 10 μg | 1 μg/μL |
Número do catálogo A36499
Preço (BRL)
7.670,87
Each
Quantity:
500 μg
Concentration:
5 μg/μL
Preço (BRL)
7.670,87
Each
Invitrogen TrueCut Cas9 Protein v2 is a next-generation CRISPR Cas9 protein engineered to deliver maximum editing efficiency.
Features include:
- Consistently high editing efficiency in all tested cell lines including standard, immune, primary, and stem, with up to 2X higher editing efficiency in difficult targets than the competition
- High quality—manufactured under strict ISO 13485 quality standards
- Validated protocols for a large number of cell types help you achieve success faster
TrueCut Cas9 Protein v2 is recombinant Streptococcus pyogenes Cas9 (wt) protein, purified from E. coli, for genome editing with CRISPR technology. Cas9 protein forms a very stable ribonucleoprotein (RNP) complex with the guide RNA (gRNA) component of the CRISPR/Cas9 system. Incorporation of nuclear localization signals (NLS) aids delivery to the nucleus, increasing the rate of genomic DNA cleavage.
- Transfection-ready, using either lipid-mediated transfection reagents or electroporation
- Eliminates time-consuming cloning steps
- Available in two concentrations:
- 1 μg/μL for use in standard editing scenarios
- 5 μg/μL for optimization of editing conditions in more difficult scenarios such as in primary or embryonic cells, microinjection, or when screening multiple gRNA sequences at a time
- For custom sizes or concentrations, please inquire
Options for obtaining CRISPR gRNA for use with TrueCut Cas9 Protein v2:
- Order pre-designed TrueGuide Synthetic gRNAs for high-efficiency knock out in human or mouse
- Submit your own design for custom synthesis of CRISPR sgRNA
- Use our free TrueDesign CRISPR Genome Editor software for easy design and ordering of custom gRNA for precise genome editing
For Research Use Only. Not for use in diagnostic procedures.
Especificações
Accession NumberNC_002737.2:854751-858857
ComponentsTrueCut Cas9 Protein v2
Expression SystemE. coli
Gene Aliascas9, cas5, csn1
Gene ID (Entrez)901176
Gene SymbolSpy_1046
GradeMolecular Biology
Product TypeCas9 Protein v2
Protein FormRecombinant
Protein TagUntagged
Quantity500 μg
Shipping ConditionDry Ice
Validated ApplicationGenome Editing
Concentration5 μg/μL
Product LineTrueCut
Research CategoryGenome Editing
Unit SizeEach
Conteúdo e armazenamento
TrueCut Cas9 Protein v2 (5 mg/mL), 500 μg
Store at -5°C to -30°C.
Store at -5°C to -30°C.
Frequently asked questions (FAQs)
What is the molecular weight of TrueCut Cas9 Protein v2?
What is the difference between TrueCut Cas9 Protein (Prototype) and TrueCutCas9 Protein v2?
Is there a specific antibody that you recommend to test the delivery of TrueCut Cas9 Protein v2?
What is the storage buffer composition for TrueCut Cas9 Protein v2 and TrueCut HiFi Cas9 Protein?
Which lipid transfection reagent do you recommend using with TrueCut Cas9 Protein v2 and TrueCut HiFi Cas9 Protein?
Citações e referências (14)
Citações e referências
Abstract
Highly efficient RNA-guided genome editing in human cells via delivery of purified Cas9 ribonucleoproteins.
Journal:
PubMed ID:24696461
'RNA-guided engineered nucleases (RGENs) derived from the prokaryotic adaptive immune system known as CRISPR (clustered, regularly interspaced, short palindromic repeat)/Cas (CRISPR-associated) enable genome editing in human cell lines, animals, and plants, but are limited by off-target effects and unwanted integration of DNA segments derived from plasmids encoding Cas9 and guide
Rapid and highly efficient mammalian cell engineering via Cas9 protein transfection.
Journal:
PubMed ID:26003884
'CRISPR-Cas9 systems provide a platform for high efficiency genome editing that are enabling innovative applications of mammalian cell engineering. However, the delivery of Cas9 and synthesis of guide RNA (gRNA) remain as steps that can limit overall efficiency and ease of use. Here we describe methods for rapid synthesis of
Precise Correction of Heterozygous SHOX2 Mutations in hiPSCs Derived from Patients with Atrial Fibrillation via Genome Editing and Sib Selection.
Journal:Stem Cell Reports
PubMed ID:32976766
'Patient-specific human induced pluripotent stem cells (hiPSCs) offer unprecedented opportunities for the investigation of multigenic disease, personalized medicine, and stem cell therapy. For heterogeneous diseases such as atrial fibrillation (AF), however, precise correction of the associated mutation is crucial. Here, we generated and corrected hiPSC lines from two AF patients
Efficient gene knockout in primary human and murine myeloid cells by non-viral delivery of CRISPR-Cas9.
Journal:J Exp Med
PubMed ID:32357367
'Myeloid cells play critical and diverse roles in mammalian physiology, including tissue development and repair, innate defense against pathogens, and generation of adaptive immunity. As cells that show prolonged recruitment to sites of injury or pathology, myeloid cells represent therapeutic targets for a broad range of diseases. However, few approaches
Precise and error-prone CRISPR-directed gene editing activity in human CD34+ cells varies widely among patient samples.
Journal:Gene Ther
PubMed ID:32873924
'Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) and their associated CRISPR-associated nucleases (Cas) are among the most promising technologies for the treatment of hemoglobinopathies including Sickle Cell Disease (SCD). We are only beginning to identify the molecular variables that influence the specificity and the efficiency of CRISPR- directed gene editing,